Welcome to the e-CCO Library!

P446: Long-term Clinical Effectiveness And Stoma Outcome Of Fecal Diversion In Refractory Crohn’s Proctitis
Year: 2022
Source: ECCO'22
Authors: Benammi, S.(1);Perry, W.R.(1);Calini, G.(1);Abdalla, S.(1);Shawki, S.F.(1);Larson, D.W.(1);Mathis, K.L.(1);
Created: Friday, 11 February 2022, 3:52 PM
P446: Patient and public involvement in a clinical trial for perianal Crohn’s fistula
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Sahnan1*, A. Verjee2, S. Blackwell3, R. Sawyer2, S. Mannick4, M.J. Lee5, S.O. Adegbola1, P.J. Tozer1, N. Heywood6, A.L. Hart7, N.S. Fearnhead8

Created: Thursday, 21 February 2019, 9:14 AM
P446: Plasma rich in growing factors as treatment for perianal fistulas in Crohn’s disease: unicentre experience.
Year: 2021
Source: ECCO'21 Virtual
Authors: Soto Sánchez, A.(1);Hernandez Camba, A.(2);Hernández, M.(1);Hernández, G.(1);Pérez Sánchez, E.(1);Barrera Gómez, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P446: The INTESTINE study: INtended TEmporary STomas In crohN's diseasE
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Perrott, C.(1)*;Calini, G.(2);Gori, A.(3);Rottoli, M.(3);Garoufalia, Z.(4);Wexner, S.(4);Celentano, V.(1);
Created: Friday, 14 July 2023, 11:05 AM
P447 No severe neonatal and maternal complications in inflammatory bowel diseases patients treated with ustekinumab or vedolizumab during pregnancy
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. Wils1, P. Seksik2, C. Stefanescu3, S. Nancey4, M. Allez5, D. Laharie6, G. Pineton De Chambrun7, R. Altwegg7, C. Gilletta8, L. Vuitton9, S. Viennot10, M. Serrero11, M. Fumery12, G. Savoye13, M. Collins14, F. Goutorbe15, H. Brixi16, G. Bouguen17, N. Tavernier18, M. Boualit19, A. Amiot20, V. Abitbol21, B. Pariente22

Created: Thursday, 30 January 2020, 10:12 AM
P447: Combined fibrin glue with infliximab therapy of postoperative anastomotic fistula in patients with Crohn`s disease:A Pilot study
Year: 2021
Source: ECCO'21 Virtual
Authors: Li, Y.(1);Yao, D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P447: Early predictors of the need for surgery in patients with acute severe ulcerative colitis: results of the prospective, observational, international ESCP MASC study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Frasson, M.(1);Pinkney, T.(2);Gisbert, J.P.(3);Rodriguez-Lago, I.(4);Blackwell, S.(5);Gecse, K.B.(6);Buskens , C.J.(7);Knowles, C.(8);Zmora, O.(9);Brookes, M.(10);Fiorino, G.(11);Nos, P.(12);Gallo, G.(13);Pata, F.(14);Verjee, A.(15);Leone, S.(16);PellinoMD- PhD- FRCS- FEBS Colo- FASCRS- FACS, G.(17)*;
Created: Friday, 14 July 2023, 11:05 AM
P447: Infliximab trough levels are decreasing overtime in patients with inflammatory bowel disease on maintenance treatment with infliximab
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Orfanoudaki1*, M. Gazouli2, K. Foteinogiannopoulou1, E. Theodouraki1, E. Legaki2, I. Koutroubakis1

Created: Thursday, 21 February 2019, 9:14 AM
P447: Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Alsoud, D.(1);Sabino, J.(1,2);Ferrante, M.(1,2);vermeire, S.(1,2);Verstockt , B.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
P447: Seasonal variations in Vitamin D concentrations in a single-centre inflammatory bowel disease series
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Vernia*, G. Burrelli Scotti, M. T. Afferri, V. Vaiarello

Created: Friday, 22 February 2019, 9:49 AM
P447: The impact of therapeutic drug monitoring during biosimilar infliximab switch in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Ranjan*1, S. Myers2, L. Crissop1, S. Ritchie1, F. Maw1, S. Sebastian2, A. Dhar1

Created: Friday, 22 February 2019, 9:41 AM
P447: Vedolizumab induces significantly higher endoscopic remission rates at week 16 in ulcerative colitis as compared to Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Pauwels R.W.M., De Vries A.C., Van der Woude C.J.

Created: Wednesday, 20 February 2019, 10:36 AM
P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Danese1, R. Panaccione2, L. Peyrin-Biroulet3, C. Marano4, C.D. O’Brien4, H. Zhang5, Y. Zhou5, J. Johanns5, E. Scherl6, R.W.L. Leong7, D.S. Rowbotham8, R.P. Arasaradnam9, B.E. Sands10

Created: Thursday, 30 January 2020, 10:12 AM
P448: Biologic therapy and immunodulators are associated with decreased risk of cardiovascular events in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Fumery M.*1, Singh A.2, Khera R.3, Prokop L.4, Curtis J.5, Sandborn W.6, Singh S.6

Created: Wednesday, 20 February 2019, 10:36 AM
P448: Cannabis and cannabinoids for the treatment of inflammatory bowel disease: a systematic review and meta-analysis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Doeve1, F. van Schaik*1, M. van de Meeberg1, H. Fidder1

Created: Friday, 22 February 2019, 9:41 AM
P448: IBD nurse in patients’ health status assessment: data from a pilot study comparing ability of IBD nurse and gastroenterologist in using IBD clinical scores
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

F. Mocciaro*1, R. Di Mitri1, G. M. Pecoraro1, D. Scimeca2, G. Russo1, F. Bossa2, V. Costanza1, D. Varvara2, M. A. Profita1, G. Profeta1, G. Martino2

Created: Friday, 22 February 2019, 9:49 AM
P448: Long term effectiveness of first-line infliximab treatment compared to conventional treatment in paediatric moderate-to-severe Crohn's disease – an update from the TISKids study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vuijk, S.(1)*;Jongsma, M.(1);Cozijnsen, M.(1);van Pieterson, M.(1);de Meij, T.(2);Norbruis, O.(3);Groeneweg, M.(4);Wolters, V.(5);van Wering, H.(6);Hojsak, I.(7);Kolho, K.L.(8);Hummel, T.(9);Stapelbroek, J.(10);van der Feen, C.(11);van Rheenen, P.(12);van Wijk, M.(2);Teklenburg, S.(3);Escher, J.(1);de Ridder, L.(1);
Created: Friday, 14 July 2023, 11:05 AM
P448: Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
Year: 2022
Source: ECCO'22
Authors: Kim, K.(1);Hong, H.S.(1);Oh, K.(1);Lee, J.Y.(1);Hong, S.W.(1);Park, J.H.(1);Hwang, S.W.(1,2);Yang, D.H.(1);Byeon, J.S.(1);Ye, B.D.(1,2);Myung, S.J.(1);Yang, S.K.(1,2);Park, S.H.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
P448: Remission induction therapy with tacrolimus and biological combination therapy for severe ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Ito*

Created: Thursday, 21 February 2019, 9:14 AM
P448: Safety of anti-TNF introduction following tuberculosis treatment in Inflammatory Bowel Disease patients in an endemic area
Year: 2021
Source: ECCO'21 Virtual
Authors: Azevedo, M.F.C.D.(1);Justus, F.F.(1);Lima, C.C.G.(1);Garcia, K.S.(1);Barros, L.L.(1);Oba, J.(1);Carlos, A.D.S.(1);Milani, L.R.(1);Sipahi, A.M.(1);Damião, A.O.M.C.(1);Queiroz, N.S.F.(1);
Created: Wednesday, 2 June 2021, 4:12 PM